New drug could help ease breathing problems: Experimental meds could help people with chronic lung conditions
A new drug could help millions with lung conditions such as asthma and emphysema, which cause symptoms ranging from coughing to severe breathing difficulties.
The drug blocks excess mucus production in the respiratory tract. Mucus plays a crucial role in keeping our lungs and airways healthy by maintaining moisture and trapping particles such as dust and microbes which might cause irritation or infection.
Tiny hair-like cells called cilia, which move in a wave-like motion, then transport the mucus containing unwanted microbes and other substances out of the body in phlegm.
A new drug could help millions with lung conditions such as asthma and emphysema, which cause symptoms ranging from coughing to severe breathing difficulties
But people with conditions such as asthma, viral infections, cystic fibrosis and chronic obstructive pulmonary disease (COPD) — an umbrella term for chronic lung conditions, including emphysema — can produce too much mucus.
In some cases this can lead to a life-threatening build-up of it that can entirely obstruct the airway.
Current treatments include steroid inhalers to dampen down the inflammation which promotes mucus build-up in those with asthma, and mucus-thinning medication for those with COPD and cystic fibrosis.
But now scientists have discovered an alternative.
The experimental drug, called PEN-SP9, blocks the effect of a protein involved in the over-production of mucus.
The drug was developed by scientists from the University of Texas and Stanford University, both in the U.S., to tackle the protein called synaptotagmin.
People with conditions such as asthma, viral infections, cystic fibrosis and chronic obstructive pulmonary disease (COPD) — an umbrella term for chronic lung conditions, including emphysema — can produce too much mucus
This binds to calcium molecules that are released by inflamed cells in the lungs, triggering a reaction between the two that ramps up mucus production.
The new drug stops synaptotagmin from binding to the calcium molecules. ‘This is the first compound that specifically alleviates the pathological hypersecretion of mucus,’ the researchers said.
The journal Nature reported earlier this year that, when the scientists tested the drug on mice, it reduced mucus production to normal, healthy levels without eliminating it completely. Human trials could begin in two to three years.
Commenting on the research, Professor James Chalmers, a consultant respiratory physician at Ninewells Hospital in Dundee and the chairman of the British Thoracic Society’s science and research committee, said: ‘At the moment, we have lots of drugs for respiratory disease but we don’t really have good drugs that reduce mucus production.
‘This is an exciting development but it is in very early stages.’
Over-production of a mucus protein could actually protect some people with allergic asthma against Covid.
It’s well known that those with asthma triggered by allergies tend to produce more of the mucus protein MUC5AC.
Now lab studies by scientists at the University of North Carolina in the U.S. have shown that ‘allergic airways’ that release more of the inflammatory protein IL-13 and produce more MUC5AC were able to block the virus from spreading, reports the journal Proceedings of the National Academy of Sciences.
Stress can affect female fertility, according to a study in the journal Endocrinology.
When researchers exposed rats to scream sounds for three weeks — a common stress test — it reduced levels of hormones involved in fertility and lowered the number and quality of eggs and resulted in smaller litters.